Almanya - Almanca - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

chemi pharma ltd. (1010499) - pemetrexed-dinatrium 2.5 h<2>o - pulver für ein konzentrat zur herstellung einer infusionslösung - teil 1 - pulver für ein konzentrat zur herstellung einer infusionslösung; pemetrexed-dinatrium 2.5 h<2>o (41929) 606,9 milligramm

Almanya - Almanca - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

chemi pharma ltd. (1010499) - pemetrexed-dinatrium 2.5 h<2>o - pulver für ein konzentrat zur herstellung einer infusionslösung - teil 1 - pulver für ein konzentrat zur herstellung einer infusionslösung; pemetrexed-dinatrium 2.5 h<2>o (41929) 127,45 milligramm

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - karzinom, plattenepithelkarzinom - antineoplastische mittel - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Belçika - Almanca - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

baxter - faktor xiii; aprotinin; human-thrombin; calcium-chlorid dihydrat; human-fibrinogen - lösung für gewebekleber; lösung für gewebekleber - 2 ml - faktor xiii ; aprotinin ; human-thrombin 500 iu/ml; calcium-chlorid dihydrat ; human-fibrinogen - combinations

Belçika - Almanca - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

baxter - human-fibrinogen; faktor xiii; human-thrombin; aprotinin; calcium-chlorid dihydrat - lösung für gewebekleber; lösung für gewebekleber - 4 ml - human-fibrinogen ; faktor xiii ; human-thrombin ; aprotinin ; calcium-chlorid dihydrat - combinations

Belçika - Almanca - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

baxter - human-fibrinogen; faktor xiii; human-thrombin; aprotinin; calcium-chlorid dihydrat - lösung für gewebekleber; lösung für gewebekleber - 10 ml - human-fibrinogen ; faktor xiii ; human-thrombin ; aprotinin ; calcium-chlorid dihydrat - combinations

Avrupa Birliği - Almanca - EMA (European Medicines Agency)

blueprint medicines (netherlands) b.v. - avapritinib - gastrointestinale stromatumoren - andere antineoplastische wirkstoffe, die protein-kinase-inhibitoren - ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (gist) harbouring the platelet-derived growth factor receptor alpha (pdgfra) d842v mutation.

Belçika - Almanca - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

iason - fluorocholine (f-18) - injektionslösung - 1 gbq/ml - fluorocholine (f-18) - fluoromethylcholine (18f)